Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1000

Benzinga · 2d ago
Guggenheim analyst Brad Canino maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $995 to $1000.